The FDA has approved Rybrevant (amivantamab) in combination with chemotherapy to treat advanced, EGFR-mutant NSCLC that progressed on or after treatment with an EGFR TKI.

(HealthDay News) — Among cancer survivors, excess body weight is associated with an increased risk of a second primary cancer, according to a study published in JAMA Network Open.

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.

Adding radium-223 to treatment with enzalutamide and a bone-protecting agent improved rPFS and OS in patients with mCRPC and ...

Retifanlimab improved upon standard chemotherapy in patients with locally recurrent or metastatic anal cancer in a phase 3 ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Source: Getty Images Results from DESTINY-Breast12 support the use of T-DXd for patients with HER2-positive metastatic breast cancer with or without brain metastases, according to Nancy U.

Moderately hypofractionated nodal radiotherapy is not inferior to normofractionated radiotherapy for early breast cancer, data suggest.

Source: Getty Images Capivasertib did not improve survival in the overall population or in patients with PIK3CA, AKT1, or PTEN-altered tumors. The median overall survival was 17.7 months in ...

Source: Getty Images Researchers observed positive results with ivonescimab, N-803, aumolertinib, sacituzumab govitecan, ifinatamab deruxtecan, durvalumab-based combinations, and amivantamab and ...

Source: Getty Images Palbociclib plus retifanlimab produced confirmed responses in 14% of patients and unconfirmed responses in 21%. The median duration of response was not reached. The ...